Nykode Therapeutics AS Ordinary Shares NYKD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NYKD is a good fit for your portfolio.
News
-
Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical Cancer
-
Nykode Therapeutics - Quarterly report Q1 2024
-
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
-
Nykode Therapeutics Announces Topline Conclusions Affirming Prolonged Clinical Benefits from Matured Survival Data in Phase 2 C-02 Trial in Advanced Cervical Cancer
-
Nykode Therapeutics Announces Advances in the Inverse Vaccine Platform With the Potential to Treat Autoimmune Diseases
Trading Information
- Previous Close Price
- NOK 14.73
- Day Range
- NOK 14.52–14.95
- 52-Week Range
- NOK 12.38–30.86
- Bid/Ask
- NOK 14.25 / NOK 15.70
- Market Cap
- NOK 4.79 Bil
- Volume/Avg
- 459,602 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 39.42
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nykode Therapeutics AS is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunotherapies. The company is developing individualized cancer neoantigen vaccines and is using the Vaccibody technology to generate therapeutics to treat cancers with a high unmet medical need.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 176
- Website
- https://www.nykode.com
Comparables
Valuation
Metric
|
NYKD
|
CGEM
|
PTGX
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | 12.90 |
Price/Book Value | 2.73 | 2.53 | 3.29 |
Price/Sales | 39.42 | — | 6.00 |
Price/Cash Flow | — | — | 9.86 |
Price/Earnings
NYKD
CGEM
PTGX
Financial Strength
Metric
|
NYKD
|
CGEM
|
PTGX
|
---|---|---|---|
Quick Ratio | 8.43 | 16.60 | 15.61 |
Current Ratio | 8.43 | 17.07 | 15.72 |
Interest Coverage | — | — | — |
Quick Ratio
NYKD
CGEM
PTGX
Profitability
Metric
|
NYKD
|
CGEM
|
PTGX
|
---|---|---|---|
Return on Assets (Normalized) | −18.26% | −24.60% | 51.28% |
Return on Equity (Normalized) | −23.64% | −25.95% | 56.32% |
Return on Invested Capital (Normalized) | −26.98% | −29.67% | 51.24% |
Return on Assets
NYKD
CGEM
PTGX
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Hqgnyndyn | Vsbnb | $586.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Nsbtcwrv | Nphrzq | $110.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vkvbmwppj | Knvkds | $107.8 Bil | |
MRNA
| Moderna Inc | Mbmgyfng | Mpdk | $48.2 Bil | |
BNTX
| BioNTech SE ADR | Xcfvddhsy | Tysgv | $22.2 Bil | |
ARGX
| argenx SE ADR | Flnkgpkn | Jznx | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jfklzys | Tvtly | $18.6 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Ddthsvt | Ttbsks | $15.1 Bil | |
INCY
| Incyte Corp | Crgtqdxs | Ytbrwz | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Nyglbhywp | Ypsnttt | $12.7 Bil |